Literature DB >> 29264714

From a direct oral anticoagulant to warfarin: reasons why patients switch.

Aisling Barrett1, Margaret Moore2, Patricia Ferrins2, Patrick Thornton2, Philip Murphy2, John Quinn2.   

Abstract

The introduction of the direct oral anticoagulants (DOACs) has led to their widespread use for stroke prevention and venous thromboembolism, but little is known about the numbers of patients switching from a DOAC to (or back to) a warfarin or the reasons for doing so. This study was an analysis of prospectively collected data from a 4-year period surveying a warfarin dose adjustment clinic in a large city centre hospital with the primary objective to identify these reasons. In our clinic with 1791 patients annually under review, 40 patients were identified as having switched from a DOAC to warfarin with the most common reasons for switching being bleeding, re-thrombosis and renal deterioration. Other reasons included medication interactions, side effects, antiphospholipid syndrome, valvular replacement or arterial embolism. Clinical events following warfarin commencement were also recorded. Overall, these data suggest that switching from a DOAC to warfarin is seldom deemed necessary by clinicians. However, as the number of patients receiving DOACs continues to increase, it is vital that health care professionals remain vigilant regarding medication interactions, bleeding risk and changing renal function.

Entities:  

Keywords:  Coagulation; Direct oral anticoagulants; Haematology; Warfarin

Mesh:

Substances:

Year:  2017        PMID: 29264714     DOI: 10.1007/s11845-017-1730-9

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  7 in total

Review 1.  Old and new oral anticoagulants: Food, herbal medicines and drug interactions.

Authors:  Alessandro Di Minno; Beatrice Frigerio; Gaia Spadarella; Alessio Ravani; Daniela Sansaro; Mauro Amato; Joseph P Kitzmiller; Mauro Pepi; Elena Tremoli; Damiano Baldassarre
Journal:  Blood Rev       Date:  2017-02-05       Impact factor: 8.250

Review 2.  Drug Hepatotoxicity: Newer Agents.

Authors:  Chalermrat Bunchorntavakul; K Rajender Reddy
Journal:  Clin Liver Dis       Date:  2016-10-14       Impact factor: 6.126

3.  Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant.

Authors:  Zachary D Hale; Xiowen Kong; Brian Haymart; Xiaokui Gu; Eva Kline-Rogers; Steve Almany; Jay Kozlowski; Gregory D Krol; Scott Kaatz; James B Froehlich; Geoffrey D Barnes
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

Review 4.  Reversal of direct oral anticoagulants: a practical approach.

Authors:  Andrew W Shih; Mark A Crowther
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

5.  Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.

Authors:  Menno V Huisman; Kenneth J Rothman; Miney Paquette; Christine Teutsch; Hans Christoph Diener; Sergio J Dubner; Jonathan L Halperin; Changsheng Ma; Kristina Zint; Amelie Elsaesser; Dorothee B Bartels; Gregory Y H Lip
Journal:  Am J Med       Date:  2015-08-01       Impact factor: 4.965

6.  High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy.

Authors:  Beenish S Manzoor; Surrey M Walton; Lisa K Sharp; William L Galanter; Todd A Lee; Edith A Nutescu
Journal:  J Thromb Thrombolysis       Date:  2017-11       Impact factor: 2.300

Review 7.  DOACs - advances and limitations in real world.

Authors:  Lai Heng Lee
Journal:  Thromb J       Date:  2016-10-04
  7 in total
  1 in total

1.  Implementing a Rapid Response System in a tertiary-care hospital. A cost-effectiveness study.

Authors:  G Muñoz-Rojas; B García-Lorenzo; D Esteve; S Trias; D Caellas; M Sanz; R Mellado; T Peix; L Sampietro-Colom; N Pou; G Martínez-Pallí; Carlos Ferrando
Journal:  J Clin Monit Comput       Date:  2022-04-23       Impact factor: 1.977

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.